Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Short term Debt (2020 - 2022)

Historic Short term Debt for Arcturus Therapeutics Holdings (ARCT) over the last 3 years, with Q4 2022 value amounting to $60.7 million.

  • Arcturus Therapeutics Holdings' Short term Debt rose 16988.97% to $60.7 million in Q4 2022 from the same period last year, while for Dec 2022 it was $60.7 million, marking a year-over-year increase of 16988.97%. This contributed to the annual value of $60.7 million for FY2022, which is 16988.97% up from last year.
  • Latest data reveals that Arcturus Therapeutics Holdings reported Short term Debt of $60.7 million as of Q4 2022, which was up 16988.97% from $27.7 million recorded in Q3 2022.
  • Arcturus Therapeutics Holdings' 5-year Short term Debt high stood at $60.7 million for Q4 2022, and its period low was $1.2 million during Q4 2020.
  • In the last 3 years, Arcturus Therapeutics Holdings' Short term Debt had a median value of $22.5 million in 2021 and averaged $21.1 million.
  • Per our database at Business Quant, Arcturus Therapeutics Holdings' Short term Debt skyrocketed by 169792.0% in 2021 and then surged by 4988.64% in 2022.
  • Quarter analysis of 3 years shows Arcturus Therapeutics Holdings' Short term Debt stood at $1.2 million in 2020, then surged by 1697.92% to $22.5 million in 2021, then surged by 169.89% to $60.7 million in 2022.
  • Its last three reported values are $60.7 million in Q4 2022, $27.7 million for Q3 2022, and $27.0 million during Q2 2022.